Expert-Driven Psychiatry Case: LAIs for Schizophrenia: Review the Data, Ep4

Before selecting a treatment path for schizophrenia, review the latest research data. Christoph Correll, MD presents the latest insights and data that support the introduction of long acting injectable (LAI) antipsychotics for patients with schizophrenia for whom oral medication alone has not had successful or desired outcomes. In episode 4, Correll will show:

- Survey of 206 schizophrenia patients who used LAI for 3+ months
- Benefits of LAI during first episode
- Non-adherence with oral medication is most common and preventable cause of relapse
- Positive perceptions of LAI by patients, caregivers, and clinicians alike

-- - - - -
Presented by The Journal of Clinical Psychiatry.

Christoph Correll, MD, is professor of psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and a medical director of the Recognition and Prevention (RAP) program at Zucker Hillside Hospital.